Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry.
Daniele ArmeniaVincenzo SpagnuoloMaria C BellocchiLaura GalliLeonardo DucaGreta MarchegianiTommaso ClementeLuca CariotiRiccardo LolattoLeonardo CalzaBenedetto M CelesiaAntonio CascioDaniela FrancisciAnnalisa SaracinoCarlo TortiMaurizio ZazziAntonella CastagnaMaria-Mercedes Santoronull nullPublished in: The Journal of antimicrobial chemotherapy (2024)
In non-viraemic people with an MDR virus, HIV-1 DNA NGS set at 5% is an acceptable technical cut-off that might help to reveal mutations with a potential clinical relevance. Moreover, the number of minority resistance mutations additionally detected by NGS might be associated with loss of virological control.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- multidrug resistant
- human immunodeficiency virus
- hiv testing
- hiv infected patients
- hiv aids
- circulating tumor
- hepatitis c virus
- men who have sex with men
- cell free
- drug resistant
- gram negative
- acinetobacter baumannii
- escherichia coli
- genome wide
- electronic health record
- nucleic acid
- big data
- gene expression
- single cell
- cystic fibrosis
- dna methylation
- pseudomonas aeruginosa
- machine learning
- deep learning